It was assumed initially that Alzheimer’s Disease was a rare condition, but now it is considered to be an inevitable consequence of aging. Alzheimer's disease (AD) is a neurodegenerative disorder that results in cognitive ability and most commonly affects individuals with the age of 65 years and above. It is estimated that in 2021 in America alone about 6.2 million Americans of age 65 and older are living with AD. Previously approved therapies are intended to treat the cognitive symptoms associated with AD. The last decade has noticed a steady increase in efforts directed at discovering and developing a novel pharmacological treatment to treat AD. Advances in the identification of biomarkers for Alzheimer’s have drawn attention towards the early diagnosis of the disease, allowing delaying the cognitive decline with the emerging therapies. The new disease-modifying therapies under development comprise almost 80% of upcoming therapies, representing a potential step to change the treatment.&nbsp;They may be available in the next years for patients with Alzheimer’s disease. Several clinical trial have been designed to evaluate the drug candidates that target the pathophysiology of the disease.Through Alzheimer’s disease whitepaper, DelveInsight will draw your attention towards the current treatment picture of Alzheimer’s along with the future therapies in the coming decade. The whitepaper summarizes the approved therapies, ongoing clinical trials at different stages of development, several pharma and biotech companies involved in the domain. This paper also highlights the mechanism of novel therapies being developed, the product type, emphasis on designation, collaboration/ licensing agreements, and future advancements. In addition, the paper also underlines the various market barriers and drivers in the area. Through this whitepaper, the reader can get an overview of the future developments in the universe of <a href="https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight" rel="noopener noreferrer" target="_blank">Alzheimer's Disease therapies</a>.Do check out our recent blog on <a href="https://www.delveinsight.com/blog/alzheimers-disease-pipeline" rel="noopener noreferrer" target="_blank">Drug Development and Pipeline Analysis in the Alzheimer’s Disease Market Space</a>.

It was assumed initially that Alzheimer’s Disease was a rare condition, but now it is considered to be an inevitable consequence of aging. Alzheimer disease (AD) is a neurodegenerative disorder that results in cognitive ability and most commonly affects individuals with age of 65 years and above. It is estimated that in 2021 in America alone about 6.2 million Americans of age 65 and older are living with AD.

Drug discovery to clinical development: Alzheimer’s disease treatment on the verge to change

Alzheimer’s disease whitepaper, DelveInsight will draw your attention towards the current treatment picture of Alzheimer’s along with the future therapies in the coming decade